Atypical antipsychotics may be an appropriate option to alleviate behavioural symptoms in some children with pervasive developmental disorders

    loading  Checking for direct PDF access through Ovid

Abstract

Individualized behavioural therapy intervention and pharmacotherapy play vital roles in the treatment of pervasive developmental disorders (PDDs) in children. Atypical antipsychotics may be useful in alleviating certain symptoms associated with PDDs, such as aggression, irritability and self-injurious behaviour. The largest amount of clinical evidence is available for risperidone, which has consistently shown improvements in behavioural symptoms associated with autistic disorder and other PDDs. Although clinical trial data for other atypical antipsychotics in PDD are limited, ziprasidone and aripiprazole have shown promise, whereas olanzapine and quetiapine have shown minimal clinical benefit

Related Topics

    loading  Loading Related Articles